Ionis Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brett Monia
- Full Time Employees
- 1,480
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2855 Gazelle Court Carlsbad CA United States of America 92010
- IPO Date
- May 17, 1991
- CIK
- 0000874015
- Website
- ionis.com
- Similar Companies
- Business
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) develops and commercializes RNA-targeted therapeutics for patients with rare diseases and other unmet medical needs. The company utilizes its proprietary antisense technology platform to design drugs that modulate RNA and protein expression; its marketed products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Waylivra (volanesorsen) for rare cardiovascular and metabolic diseases; and its pipeline encompasses candidates such as pelacarsen for cardiovascular disease, olezarsen for familial chylomicronemia syndrome and familial partial lipodystrophy, and donidalorsen for hereditary angioedema. Ionis operates primarily in the biotechnology sector, targeting pharmaceutical companies through licensing agreements and direct commercialization in select markets, with global operations spanning the United States, Europe, and other regions. Founded in 1989 and headquartered in Carlsbad, California, the company maintains subsidiaries including Akcea Therapeutics, which focuses on commercializing certain antisense medicines prior to its integration into Ionis. In recent developments, Ionis completed the acquisition of certain assets from Novartis in 2024, including rights to pelacarsen; announced positive Phase 3 topline results for olezarsen in severe hypertriglyceridemia in mid-2025; and entered a strategic collaboration with Moderna in late 2024 to develop antisense-based therapies for cardiovascular indications. Additionally, the company reported its Q3 2025 financial results in November 2025, highlighting pipeline advancements and royalty revenues exceeding $200 million from Spinraza, alongside preparations for multiple regulatory filings in 2026.
Company News
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
US FDA approves Ionis Pharma's therapy to treat rare brain disorder
Ionis to present at upcoming investor conferences
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
ADAR1 Capital Management LLC Acquires Shares of 166,286 Ionis Pharmaceuticals, Inc. $IONS
Breakfast News: A Conversation With Ionis CEO
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
Insider Buying: Ionis Pharmaceuticals (NASDAQ:IONS) Director Buys $800,700.00 in Stock
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook